IL-17 and brain changes that link psoriatic disease to depressive symptoms

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults with psoriasis or psoriatic arthritis who are starting IL-17–targeting biologics as part of routine care will undergo detailed brain imaging, blood immune profiling, and mood assessments before and after treatment. The study focuses on measuring glutamate concentration in the nucleus accumbens, functional connectivity metrics, and peripheral inflammatory markers to track biological changes with IL-17 antagonism. Clinical depressive symptoms will be collected alongside imaging and blood data to link biological signals to mood changes. Findings will compare treated participants and appropriate controls to identify mechanistic links between peripheral inflammation and brain circuitry.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults ≥18 years \< 75years
* Diagnosis of PsO or PsA, made by a dermatologist or rheumatologist.
* Selected to start secukinumab/ bimekizumab/ Ixekizumab as part of their standard clinical care by their usual dermatology team for PsO or rheumatology clinical team for PsA in line with the license for secukinumab/ bimekizumab/ Ixekizumab and NICE/SMC criteria.
* No contraindications to MRI (for example metal fragments or implantable devices not compatible with MRI. (no extra x-ray images will be obtained to check placement of metal fragments or clips insitu. Existing images may be used to check for possible contraindications)
* Satisfactory completion of standard pre-biologic safety screening (including, but not limited to, exclusion of latent TB infection according to local protocol, chest X-ray, negative HIV screen, negative Hepatitis screen antibody, negative Hepatitis B surface antigen \[Hep B sAg\] and negative Hepatitis B anti-core antibody \[Hep B cAb\])
* Recent (but not within 4 weeks prior baseline) use of intra-muscular or intra-articular steroid injections
* Women of Child-Bearing Potential (WoCBP) must be willing to use effective contraception for study duration. Further information is provided in appendix 1.
* Willing to participate and give informed consent

Exclusion Criteria:

* Inability to provide written informed consent
* Severe physical impairment (e.g., blindness, deafness, paraplegia).
* Clinically important, active infections e.g. active TB
* History of inflammatory bowel disease
* Pregnant or breast feeding
* Severe claustrophobia precluding MRI
* Contraindications to 7T MRI (metal implants in the ears, head or neck, microbladed/ tattooed eyebrows, metal fragments in the eyes)
* Confounding neurological disease including MS, Stroke, Traumatic Brain Injury
* Previous exposure to IL-17A, IL-17A/F, IL-17R inhibitors or IL-23 p19/p40 inhibitors in the last 6 months
* Hypersensitivity to any of the excipients in secukinumab/ bimekizumab/ ixekizumab.
* Any reason which, at the investigator's discretion, would make them unsuitable to take part in the study.

Where it's running

• Queen Elizabeth University Hospital
  Glasgow, Scotland, United Kingdom Recruiting

Study contacts

• Principal investigator: Jonathan Cavanagh, MD, PhD — University of Glasgow
• Study coordinator: Maxine Arnott, BSc
• Email: maxine.arnott@glasgow.ac.uk
• Phone: 07890 059695

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Smartphone-supported single-session psychotherapy for postpartum depression

  A single online therapy session plus four weeks of app-based support is being tested to see if it reduces depressive symptoms in postpartum women compared with a waitlist.

  Recruiting University of Sao Paulo · São Paulo, São Paulo · NCT07925762

• Mindful Smartphone Use: A Mindfulness-Based Program for Teens with Sleep and Mood Challenges

  This study tests Mindwire, a mindfulness-based program, to see if it helps teens with problematic phone use who also have depression or anxiety.

  Recruiting Brown University · Providence, Rhode Island · NCT07892807

• Tele-based wellbeing centres for women's mental health in Bangladesh

  A randomized trial tests whether tele-counselling for depression and anxiety in Bangladeshi women is as effective as in-person counselling.

  Recruiting at 2 sites International Centre for Diarrhoeal Disease Research, Bangladesh · Chāndpur, Matlab Dakshin and 1 other locations · NCT07890896

• Remote monitoring for adults with depression using ThIA Suivi

  This study tests whether adding the ThIA Suivi remote monitoring tool to usual psychiatric care helps adults with depression feel more improved after 3 months compared with standard care alone.

  Recruiting at 3 sites Phase 1 ThIA Santé Mentale · Bron and 2 other locations · NCT07878754

• HBOT to see if it helps cognition and well‑being in first responders with prior brain injury

  This study tests whether 40 hyperbaric oxygen therapy sessions can improve thinking skills and post-concussion symptoms in current or former first responders with a history of brain injury.

  Recruiting Phase 2 Summit Hyperbarics and Wellness · Boise, Idaho · NCT07852728

• Focused ultrasound for mood and anxiety disorders

  This study tests whether repeated low-intensity focused ultrasound using the ATTN201 device can help people with subsyndromal to moderate depression, anxiety, or OCD.

  Recruiting Attune Neurosciences Inc · San Francisco, California and 1 other locations · NCT07851038

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.